Recursion Pharmaceuticals, Inc. (RXRX)
| Market Cap | 2.19B -15.1% |
| Revenue (ttm) | 68.23M +56.2% |
| Net Income | -475.67M |
| EPS | -0.89 |
| Shares Out | 623.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,585,949 |
| Open | 3.585 |
| Previous Close | 3.500 |
| Day's Range | 3.480 - 3.645 |
| 52-Week Range | 2.770 - 5.240 |
| Beta | 1.15 |
| Analysts | Buy |
| Price Target | 7.32 (+107.87%) |
| Earnings Date | Nov 2, 2026 |
About RXRX
Recursion Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat ... [Read more]
Financial Performance
In 2025, Recursion Pharmaceuticals's revenue was $74.68 million, an increase of 26.92% compared to the previous year's $58.84 million. Losses were -$644.76 million, 39.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price target is $7.32, which is an increase of 107.87% from the latest price.
News
Recursion Pharmaceuticals Earnings Call Transcript: Q3 2026
Early activity in FAP and solid tumors, a $200M financing, and runway into 2029 underpin investment in priority programs. Registrational and expansion milestones are targeted for 2027.
Recursion Pharmaceuticals Earnings release: Q3 2026
Recursion Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Recursion Pharmaceuticals Quarterly report: Q3 2026
Recursion Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Recursion Pharmaceuticals Slides: Q3 2026
Recursion Pharmaceuticals has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 3, 2026.
Recursion Pharmaceuticals reports Q3 EPS (22c), consensus (23c)
Reports Q3 revenue $18.55M, consensus $14.81M. “To pioneer a new blueprint for making medicines with AI, we believe you have to tie together three core capabilities in one engine: uncover…
Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for ...
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps
Denver, Colorado, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced new positive Phase ...
Recursion Appoints Fred Hassan as Chair of the Board
Salt Lake City, UT, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced that its Board of...
Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3
Salt Lake City, UT, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically impr...
Recursion Pharmaceuticals price target raised to $5.90 from $5.30 at Morgan Stanley
Morgan Stanley analyst Sean Laaman raised the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.90 from $5.30 and keeps an Equal Weight rating on the shares. Published first on…
Cathie Wood’s ARK Investment buys 4.2M shares of Recursion Pharmaceuticals today
21:21 EDT Cathie Wood’s ARK Investment buys 4.2M shares of Recursion Pharmaceuticals (RXRX) today
Recursion Pharmaceuticals Stock (RXRX) Soars 15% on a $10M Milestone Payment from Sanofi
Recursion Pharmaceuticals stock gained nearly 15% on Thursday thanks to a drug candidate update and milestone payment.
Recursion Pharmaceuticals rises 15.4%
Recursion Pharmaceuticals (RXRX) is up 15.4%, or 58c to $4.32.
Recursion Pharmaceuticals reports early data from REC-1245 trial
REC-1245 is an oral molecular glue designed to exploit a synthetic-lethal vulnerability in cancers by degrading RBM39, a splicing factor that regulates genes involved in DNA repair and stress response...
Recursion Pharmaceuticals provides update on REC-4881 data
REC-4881 is designed to address both Wnt/ss-catenin initiation and MAPK evolution pathways. The opportunity was identified through unbiased phenotypic screening using Recursion’s AI foundation models,...
Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration
Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi's development pipeline, with phase 1 clinical study currently planned to begin in 2027 Potential first-in-class du...
Recursion Pharmaceuticals prices 61.54M shares of Class A common stock at $3.25
Recursion Pharmaceuticals (RXRX) announced the pricing of an underwritten offering of 61.54M shares of its Class A common stock at a price of $3.25 per share. All of the shares…
Recursion Announces Pricing of $200 Million Underwritten Offering of Class A Common Stock
Salt Lake City, UT, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and developmen...
Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone
SALT LAKE CITY, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve ...
Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals today
20:03 EDT Cathie Wood’s ARK Investment buys 1.9M shares of Recursion Pharmaceuticals (RXRX) today
Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today
20:24 EDT Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals (RXRX) today
Tempus AI, Recursion extend data license agreement, enter new license agreement
Tempus AI (TEM) announced an extension of its data license agreement with Recursion Pharmaceuticals (RXRX). Additionally, the two companies have entered into a new agreement under which Tempus will li...
Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies ...
Recursion Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company has transformed into an end-to-end AI-driven drug discovery leader, achieving significant cost reductions and clinical progress with first-in-class assets like REC-4881 and REC-1245. Strategic partnerships with Genentech and Sanofi have generated over $525 million in milestones, while a proprietary data factory and integrated AI platform drive repeatable innovation.
Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Recursion Pharmaceuticals (RXRX) to $5.30 from $5.50 and keeps an Equal Weight rating on the shares.